Rain Enhancement Technologies Holdco Inc

Rain reported a net loss of $22.1 million for the three months ended June 30, 2023, versus a net loss of $17.6 million in the same period of 2022. General and administrative expense was $5.4 million, up from $3.5 million a year earlier, and restructuring charges were $2.8 million, mainly cash severance and related employee costs. Non-cash stock-based compensation was about $0.8 million, versus $1.4 million in Q2 2022. Cash, cash equivalents, and short-term investments were $86.3 million as of June 30, 2023, and management said this provides runway into year-end 2026 in the absence of a corporate transaction and partner financing. The company said cash burn will be substantially lower in Q3 and beyond, with a significant reduction in the second half of 2023.

Avanish Vellanki framed the quarter as a major reset after the Phase 3 setback, saying Rain would “streamline operations, reprioritize its activities, and implement certain cost saving measures.” He emphasized that closing MANTRA-2 preserves capital and that the company still believes p53 reactivation is an important therapeutic strategy. His tone was pragmatic but forward-looking, focused on finding new clinical-stage opportunities and potentially using Rain’s clinical expertise to build a new pipeline.

Nelson Cabatuan highlighted the financial impact of the clinical trial spend and the workforce reduction. He cited the $22.1 million net loss, the $5.4 million in G&A, the $2.8 million restructuring charge, and the $86.3 million cash balance at quarter-end. He also said the company expects runway into year-end 2026 without a corporate transaction or partner financing, but noted that cash burn in the second half of 2023 will be significantly reduced compared with the first half and prior year.

Analysts focused on what comes next after milademetan’s failure, including whether the drug is effectively shelved, whether the RAD52 program could be restarted, and what types of assets Rain wants to license or buy. Management said there are no current plans for milademetan and no intention to deploy capital behind it, and that RAD52 has not been advanced because investment stopped more than a year ago. They also declined to give meaningful detail on target modalities or deal structure, but said they are looking broadly at clinical-stage opportunities and alternative corporate options, including a reverse merger, if an investable asset is not found.